R. Fleischmann, M. Schiff, D. M. van der Heijde
Feb 27, 2017
Citations
13
Influential Citations
306
Citations
Quality indicators
Journal
Arthritis & Rheumatology (Hoboken, N.j.)
Abstract
We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs.